ABSTRACT
Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE.
- © 2010 The Cleveland Clinic Foundation. All Rights Reserved.
Log in using your username and password
Registration is Now Required for Free Access to CCJM Content
Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.
If you are using a mobile device, click on the settings icon to access the Register link.
